MyOme and Oracle Collaborate to Advance Genomic Risk Prediction at Global Scale
24-09-2026 18:00 via prnewswire.com

MyOme and Oracle Collaborate to Advance Genomic Risk Prediction at Global Scale

MyOme's predictive genomic insights that support proactive healthcare run on Oracle Cloud Infrastructure MENLO PARK, Calif., Sept. 24, 2026 /PRNewswire/ -- MyOme, Inc., a leader in clinical whole-genome analysis and polygenic risk modeling, today announced that its predictive genomic...
Read more »

PR Public relations news



Historic Announcement: CenterPoint Energy Selected to Receive $50 Million U.S. Department of Energy Grant to Strengthen & Modernize Greater Houston's Electric Grid
Historic Announcement: CenterPoint Energy Selected to Receive $50 Million U.S. Department of Energy Grant to Strengthen & Modernize Greater Houston's Electric Grid
Global Bioinformatics Market to Reach USD 64.60 Billion by 2034, Driven by AI, Genomics, Next-Generation Sequencing, and Precision Medicine Report Maximize Market Research
Global Bioinformatics Market to Reach USD 64.60 Billion by 2034, Driven by AI, Genomics, Next-Generation Sequencing, and Precision Medicine Report Maximize Market Research
Pomerantz Law Firm Announces the Filing of a Class Action Against Fractyl Health, Inc. and Certain Officers - GUTS
Pomerantz Law Firm Announces the Filing of a Class Action Against Fractyl Health, Inc. and Certain Officers - GUTS
Pomerantz Law Firm Announces the Filing of a Class Action Against AST SpaceMobile, Inc. and Certain Officers - ASTS
Pomerantz Law Firm Announces the Filing of a Class Action Against AST SpaceMobile, Inc. and Certain Officers - ASTS
Pomerantz Law Firm Announces the Filing of a Class Action Against AppLovin Corporation and Certain Officers - APP
Pomerantz Law Firm Announces the Filing of a Class Action Against AppLovin Corporation and Certain Officers - APP
Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors - AARD
Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors - AARD
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Lincoln Educational Services Corp. of Class Action Lawsuit and Upcoming Deadlines - LINC
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Lincoln Educational Services Corp. of Class Action Lawsuit and Upcoming Deadlines - LINC
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stryker Corp. - SYK
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stryker Corp. - SYK
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ServiceTitan, Inc. - TTAN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ServiceTitan, Inc. - TTAN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of OSI Systems, Inc. - OSIS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of OSI Systems, Inc. - OSIS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of lululemon athletica inc. - LULU
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of lululemon athletica inc. - LULU
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
McCormick Declares $0.48 Quarterly Dividend
Desktop versie